According to internal sources who requested anonymity, multiple global pharmaceutical clients are closely monitoring Samsung Biologics’ ongoing labor-management conflict and have explicitly expressed ...

The chief of Samsung Biologics Co., the biotech arm of South Korea's Samsung Group, said Friday its new biomedicine ...

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

C2N Diagnostics, LLC, a specialty diagnostics company, has received a $10 million investment from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment ...

C2N Diagnostics has received a $10m strategic investment out of Samsung’s life science investment fund. The US company said ...

Samsung Biologics is planning more than 50 meetings with global big pharmaceutical companies at the upcoming DCAT Week 2025 ...

Seoul shares got off to a strong start Monday, tracking Wall Street gains, as tech giant Samsung Electronics and other tech ...

Excluding the year 2020 when the event was not held due to COVID-19, Samsung Biologics has participated in DCAT Week for ten ...

“Since Samsung C&T stepped into the life sciences industry by investing in biologics CDMO and biosimilar business, it has contributed to the stabilization of the biopharmaceutical supply chain ...

Samsung Biologics, the biotech arm of Samsung Group, said Monday that it will participate in DCAT Week 2025, taking place March 17-20 in New York, as part of its efforts to expand its global business ...

Samsung C&T announced Thursday that its Life Science Fund, established in collaboration with Samsung Biologics, Samsung ...